About SUTOL Bio
SUTOL Bio develops a swallowable capsule for people who need steady, long-term treatment. One dose each month is designed to release medicine continuously without injections. Its six programs cover five human conditions and one companion-animal condition. The human work includes opioid use disorder, schizophrenia and HIV.
Seungho Lee is co-founder and chief executive officer of the Cambridge company. Matt Murphy is co-founder and chief engineer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | Nov 10, 2026 | $474,000fully sold | 7 | $67,714 | Simple Agreement for Future Equity (SAFE)Rule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed SUTOL Bio
SUTOL Bio is developing oral drug delivery for chronic treatment. The company positions its platform between daily pills and long-acting injections. Its goal is to combine swallowing a capsule with sustained treatment.
The problem it targets
SUTOL Bio views poor adherence as the main avoidable challenge in chronic disease. Daily tablets are familiar, but missed doses can weaken treatment when caregivers are unavailable. Long-acting injections ease the daily burden, yet they can be painful and may cause injection complications. Once administered, they cannot be reversed. For companion animals, adherence also depends on owners giving each dose.
What the product does
After swallowing, the capsule remains in the stomach and releases medicine for more than 30 days. It carries drug payloads at gram scale. The design is reversible and intended for pharmacy distribution. One platform is meant to serve both human and companion-animal uses.
Progress so far
The platform emerged from six years of translational work in MIT’s Langer and Traverso laboratories. That research combined drug delivery with biomedical engineering. The work aimed to move laboratory science toward medicines for patients.
We wrote this summary from public statements by SUTOL Bio and its investors. It is not investment advice.
SUTOL Bio in the News
Leadership Team
Executive officers and directors listed on SUTOL Bio's Form D filed Nov 10, 2026.
